by Maya Caldwell | Jun 5, 2018
Pearl Pathways announces the hiring of Nancy Kant as Clinical Services Advisor to support biopharmaceutical and diagnostic life science companies. A skilled biologist, Kant brings over 35 years of experience in the pharmaceutical and diagnostics industries and...
by Maya Caldwell | Jun 5, 2018
On May 22nd, the House voted to approve a version of “right-to-try” legislation. The bill passed by a vote of 250-169. The bill is intended to help patients with life-threatening conditions, allowing them to access medicines that the Food and Drug Administration (FDA)...
by Maya Caldwell | Jun 4, 2018
On May 22, 2018, the US Food and Drug Administration (FDA) issued draft guidance for drug makers on maximal usage trials for the purpose of adding a topical active ingredient to an over-the-counter (OTC) drug monograph. A maximal usage trial is a pharmacokinetic (PK)...
by Maya Caldwell | Jun 4, 2018
As the “Brexit” deadline nears, there are several unknown questions as to how the separation will change and effect the landscape of pharmaceutical industries across Europe and possibly even the United States. The United Kingdom (UK) will not exit the European Union...
by Maya Caldwell | May 30, 2018
Gretchen Parker, IRB Co-Chair and advisor at Pearl Pathways will have her article, “A Medical Writer’s Guide for Applications to Institutional Review Boards” published in the Fall 2018 Issue of the AMWA Journal. The AMWA Journalis a nationally circulated,...
